Clinical Trial Update: A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002) [Phase 2]

View source ↗

Summary

Phase 2 study MK-2140-002 evaluating Zilovertamab vedotin (VLS-101) in solid tumors including triple-negative breast cancer and non-small-cell lung cancer was t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Non-small Cell Lung Cancer
• Pancreatic Cancer
• Platinum-resistant Ovarian Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Zilovertamab vedotin (zilovertamab vedotin)

Snippet

Sponsor: VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Conditions: Triple-negative Breast Cancer, Non-squamous Non-small-cell Lung Cancer | Phase 2 | Status: TERMINATED | Results posted: 2024-08-15